3-6 July 2019 Barcelona
![]() |
![]() |
![]() |
![]() |
1-SO | Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. | Shigenori Kadowaki | ![]() |
![]() |
|||
1-PD | Analysis of patient screening in the phase III, international, randomized, open-label APACT trial | Michele Reni | ![]() |
![]() |
|||
2-PD | CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial | SOMNATH MUKHERJEE | ![]() |
![]() |
|||
2-SO | Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-nave advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF) | Ian Chau | ![]() |
![]() |
|||
3-PD | IDENTIFICATION OF A NANOSTRING SIGNATURE THAT DIFFERENTIATES EARLY PANCREATIC CANCERS ACCORDING TO STROMAL COMPOSITION AND PREDICTS CLINICAL OUTCOME | Chiara Braconi | ![]() |
![]() |
|||
3-P | Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics | Margarita Kruchinina | ![]() |
![]() |
|||
3-LBA | A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study) | Yuko Hirano | ![]() |
![]() |
|||
4-PD | Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC | Umberto Peretti | ![]() |
![]() |
|||
4-P | Nine years of epidemiological changes of gastrointestinal cancer in Egypt | Rasha Aboelhassan | ![]() |
![]() |
|||
4-O | Applied Precision Cancer Medicine in advanced Biliary Tract Cancer | Hossein Taghizadeh | ![]() |
![]() |
|||
5-SO | A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer | Zev Wainberg | ![]() |
![]() |
|||
5-PD | Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study | Eva Hortas | ![]() |
![]() |
|||
5-P | Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma | Suna Zhou | ![]() |
![]() |
|||
6-P | miR-381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1 | wenguang ye | ![]() |
![]() |
|||
6-SO | Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers | Omar Vivar | ![]() |
![]() |
|||
6-PD | A predictive model for endoscopic ultrasonography accuracy of invasion depth in early gastric cancer | Jun Chul Park | ![]() |
![]() |
|||
7-PD | Surgical Indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cut-off value | Eva Hortas | ![]() |
![]() |
|||
7-O | ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA) | Katrina Pedersen | ![]() |
![]() |
|||
7-P | Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression. | Elvisa Kozma | ![]() |
![]() |
|||
7-LBA | Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC | Carlotta Antoniotti | ![]() |
![]() |
|||
8-PD | Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers | Aparna Parikh | ![]() |
![]() |
|||
9-P | Prognostic factors of untreated hepatocellular carcinoma on cirrhosis | STOIAN MARILENA | ![]() |
![]() |
|||
9-PD | Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC | Eva Hortas | ![]() |
![]() |
|||
10-O | VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer (EPOC 1504) | Hideaki Bando | ![]() |
![]() |
|||
10-SO | Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. | Isabelle Ahrens-Fath | ![]() |
![]() |
|||
10-PD | Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study | Andrea Casadei Gardini | ![]() |
![]() |
|||
10-P | GLOMERULAR FILTRATION RATE TO LIVER TRANSPLANTATION | STOIAN MARILENA | ![]() |
![]() |
|||
11-PD | Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis | Ismael Ghanem | ![]() |
![]() |
|||
12-P | Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer | Wanpeng Wang | ![]() |
![]() |
|||
12-PD | Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort | Erik Osterman | ![]() |
![]() |
|||
13-P | Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI | Aleksandr Polyakov | ![]() |
![]() |
|||
13-PD | RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC) | Yu Sunakawa | ![]() |
![]() |
|||
13-O | Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies | Gemma Zucchelli | ![]() |
![]() |
|||
14-P | Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life | Shuji Hiramoto | ![]() |
![]() |
|||
15-P | Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy | Shuji Hiramoto | ![]() |
![]() |
|||
15-PD | Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies | Daniele Rossini | ![]() |
![]() |
|||
16-P | Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation | DEEP CHAKRABARTI | ![]() |
![]() |
|||
16-O | Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer | Victoria Raymond | ![]() |
![]() |
|||
16-PD | Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study | Alessandra Raimondi | ![]() |
![]() |
|||
17-PD | APC I1307K and risk of colorectal neoplasia in humans and mice | Stephen Gruber | ![]() |
![]() |
|||
17-O | SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer | Jun Watanabe | ![]() |
![]() |
|||
18-PD | Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer | KO Lam | ![]() |
![]() |
|||
18-P | Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer | Youn Young Park | ![]() |
![]() |
|||
18-O | Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study | Elizabeth Alwers | ![]() |
![]() |
|||
19-PD | Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS | Claudia Cardone | ![]() |
![]() |
|||
19-P | Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer | lucheng Zhu | ![]() |
![]() |
|||
20-P | Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment | Samantha Kestenbaum | ![]() |
![]() |
|||
20-PD | Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) | Rahul Das | ![]() |
![]() |
|||
20-O | Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy | Karen Gambaro | ![]() |
![]() |
|||
21-PD | Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies | Eva Hortas | ![]() |
![]() |
|||
21-P | Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case | Abdalla Abotaleb | ![]() |
![]() |
|||
22-PD | PARP-ness in Metastatic Colorectal Cancer | Gianluca Mauri | ![]() |
![]() |
|||
22-P | Which patients on chemotherapy for colorectal cancer should be anticoagulated? | Samantha Forner | ![]() |
![]() |
|||
22-O | Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) | Donna Stefanoni | ![]() |
![]() |
|||
23-PD | Survey on the Unmet Needs of Patients Living with mCRC Learnings from an International Study | Zorana Maravic | ![]() |
![]() |
|||
24-PD | Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS | Sarah Novack | ![]() |
![]() |
|||
25-PD | Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine | Claire Palles | ![]() |
![]() |
|||
25-P | Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers | Gemma Bruera | ![]() |
![]() |
|||
25-O | A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients | filippo pietrantonio | ![]() |
![]() |
|||
26-O | Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) | Inma Ruiz de Mena | ![]() |
![]() |
|||
26-PD | Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113) | Ralf Hofheinz | ![]() |
![]() |
|||
27-PD | Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis | Daniele Rossini | ![]() |
![]() |
|||
27-P | Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP) | Ji Yeon Seo | ![]() |
![]() |
|||
28-PD | Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study. | Pia Osterlund | ![]() |
![]() |
|||
29-P | Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC) | Juan Jose Serrano Domingo | ![]() |
![]() |
|||
29-PD | Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer | OPEN Health Medical Communications | ![]() |
![]() |
|||
30-PD | Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC) | Michael Geissler | ![]() |
![]() |
|||
30-P | Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma | Hongjie Chen | ![]() |
![]() |
|||
31-PD | Immune signatures identify three immune clusters in mCRC, with potential clinical implications | Leire Pedrosa | ![]() |
![]() |
|||
31-P | Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features | Yiguang Lin | ![]() |
![]() |
|||
32-PD | Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait | Philippe Bulens | ![]() |
![]() |
|||
32-P | Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer. | Letizia Deantonio | ![]() |
![]() |
|||
33-PD | A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function | Annika Svanstrm Rjvall | ![]() |
![]() |
|||
34-PD | Clinical outcomes of rectal neuroendocrine tumors less than 20 mm: a single institutional analysis of 371 patients | Eva Hortas | ![]() |
![]() |
|||
34-P | PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer | Alison Sinclair | ![]() |
![]() |
|||
35-P | Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures | Jin-Oh Kim | ![]() |
![]() |
|||
36-P | Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer | JOLANTA ZOK | ![]() |
![]() |
|||
37-P | Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities. | Juan Luis Sanz | ![]() |
![]() |
|||
39-P | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY) | Thomas Starkey | ![]() |
![]() |
|||
40-P | Cost of metastatic colorectal cancer drugs per month of life gained in Spain | silvina grasso | ![]() |
![]() |
|||
41-P | Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients | Amer Radwi | ![]() |
![]() |
|||
43-P | Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process | Nam Hee Kim | ![]() |
![]() |
|||
46-P | Expression pattern of death receptors FasR and DR3 on NK and T cells defines the complexity of tumor-immune system interplay in esophageal cancer | Martin Snajdauf | ![]() |
![]() |
|||
50-P | The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation. | Amy Case | ![]() |
![]() |
|||
51-P | Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer | Vasileios Angelis | ![]() |
![]() |
|||
53-P | Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department | Mariam khalil | ![]() |
![]() |
|||
54-P | Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST | Hiroshi Nakatsumi | ![]() |
![]() |
|||
57-P | Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer | Pop Vlad Vasile | ![]() |
![]() |
|||
58-P | Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. | Sarah Novack | ![]() |
![]() |
|||
59-P | SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC). | Maria Loushin | ![]() |
![]() |
|||
60-P | Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years | Eleni Xenophontos | ![]() |
![]() |
|||
62-P | Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network | Po-Kuei Hsu | ![]() |
![]() |
|||
63-P | ROLE OF MAINTENANCE GEMCITABINE IN ADVANCED/METASTATIC CARCINOMA GALL BLADDER | MANISH SHARMA | ![]() |
![]() |
|||
64-P | Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study | Hee Seok Moon | ![]() |
![]() |
|||
65-P | A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study | Junichi Nakazawa | ![]() |
![]() |
|||
66-P | Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role | Gonalo Nogueira-Costa | ![]() |
![]() |
|||
69-P | Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in an ongoing phase 1 study for peritoneal metastasis | Guowei Kim | ![]() |
![]() |
|||
70-P | Esophageal cancer: 5 years of experience in a Mexican oncology reference center. | Carlos Eduardo Salazar-Mejía | ![]() |
![]() |
|||
72-P | Effects of natural substances from Boswellia sacra and Nerium oleander (breastin) in colon and pancreatic cancer | PANAGIOTIS PARSONIDIS | ![]() |
![]() |
|||
73-P | Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies | Gerardo Rosati | ![]() |
![]() |
|||
74-P | A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program | Doukens Patrick Gilbert | ![]() |
![]() |
|||
75-P | SBRT in primary and metastatic liver disease: analysis after implementation in our center | Carolina De la Pinta | ![]() |
![]() |
|||
76-P | Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features | Chinock Cheong | ![]() |
![]() |
|||
78-P | Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer | Ivica Zarev | ![]() |
![]() |
|||
80-P | Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial (PRODIGE 58 UCGI 35 REGIRI) | Laure Monard | ![]() |
![]() |
|||
82-P | Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting | Yifu He | ![]() |
![]() |
|||
83-P | FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis | Jonas Herzberg | ![]() |
![]() |
|||
85-P | Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy | Carolina De la Pinta | ![]() |
![]() |
|||
86-P | EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment | Merissa Lee | ![]() |
![]() |
|||
88-P | Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience | Rajarshi Roy | ![]() |
![]() |
|||
89-P | FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial | Yara Torres | ![]() |
![]() |
|||
92-P | Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients | Marion SONDAG | ![]() |
![]() |
|||
93-P | Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer | Felipe Oliveira | ![]() |
![]() |
|||
95-P | Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2017 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients | Julieta Grasselli | ![]() |
![]() |
|||
99-P | Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients | Emmanuelle SAMALIN | ![]() |
![]() |
|||
100-P | Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience | Michael Tilby | ![]() |
![]() |
|||
101-P | A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy | Alessandro Parisi | ![]() |
![]() |
|||
102-P | Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer. | Sayuri Konishi | ![]() |
![]() |
|||
103-P | Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study | Dai Manaka | ![]() |
![]() |
|||
104-P | Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation | Riya Gupta | ![]() |
![]() |
|||
108-P | Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 | Pasquale Lombardi | ![]() |
![]() |
|||
112-P | A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma. | PAVLOS PISKILIDIS | ![]() |
![]() |
|||
114-P | Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol | HIROAKI TANIOKA | ![]() |
![]() |
|||
115-P | The onset of grade = 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil | Jacopo Giuliani | ![]() |
![]() |
|||
116-P | GRADE evaluation of the COLOFOL randomized clinical trial | Eduardo Ceballos | ![]() |
![]() |
|||
117-P | Stage IIa colon cancer: adjuvant chemotherapy in real life | Renato Cunha | ![]() |
![]() |
|||
123-P | A Retrospective Qualitative Pilot Study Incorporating Patient Personal Life Aspects upon Admission to Palliative Care: What should we know about patients to give them the best care possible? | Anna Kitta | ![]() |
![]() |
|||
124-P | Definitive chemoradiotherapy in oesophageal cancer: Treatment outcomes from a regional cancer centre | Mohammed Abdul-Latif | ![]() |
![]() |
|||
125-P | Total neoadjuvant treatment of ugly rectal cancers in Slovenia | Vaneja Velenik | ![]() |
![]() |
|||
126-P | The management of pancreatic adenocarcinoma in a hospitalized-based population (2015-2019) | aicha bengueddach | ![]() |
![]() |
|||
128-P | Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease. | Michele Ghidini | ![]() |
![]() |
|||
129-P | Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue | RENATA DUCHNOWSKA | ![]() |
![]() |
|||
130-P | Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study | Mikhail Fedyanin | ![]() |
![]() |
|||
132-P | A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism | hongyan yu | ![]() |
![]() |
|||
133-P | A randomized, multicenter, open-label controlled phase II trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer | Peter Morsing | ![]() |
![]() |
|||
134-P | Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study | Michele Reni | ![]() |
![]() |
|||
136-P | Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types | Ralf Hofheinz | ![]() |
![]() |
|||
137-P | Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study | Skaiste Tulyte | ![]() |
![]() |
|||
138-P | Alcohol consumption and tobacco smoking and ed gastrointestinal cancers morbidity rates in Poland | Miroslaw Jarosz | ![]() |
![]() |
|||
139-P | Chemotherapy Rechallenge or Reintroduction (CTr/r), Regorafenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients: a PROpensity ScorE analysis of tReatment beyond the second liNe (PROSERpINa Study). | Maria Alessandra Calegari | ![]() |
![]() |
|||
140-P | Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib | VINCENZO RICCI | ![]() |
![]() |
|||
142-P | Sunitinib rechallenge in pancreatic neuroendocrine tumors | Vasiliki Michalaki | ![]() |
![]() |
|||
143-P | Gastric cancer: system approach | Oleg Kshivets | ![]() |
![]() |
|||
144-P | Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III | German Calderillo | ![]() |
![]() |
|||
145-P | Gastric cancer in young Latin women: bad prognostic factors and outcomes. | German Calderillo | ![]() |
![]() |
|||
147-P | Surgery specialization as a prognostic factor in colon cancer | German Calderillo | ![]() |
![]() |
|||
149-P | High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study) | Alexander Siebenhuener | ![]() |
![]() |
|||
150-P | Perioperative FLOT experience: pathological regression and toxicity | Adrián Sánchez | ![]() |
![]() |
|||
154-P | Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head | Lucia Romano | ![]() |
![]() |
|||
156-P | Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study | Vesna Bisof | ![]() |
![]() |
|||
157-P | Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen. | Nieves Martinez-Lago | ![]() |
![]() |
|||
158-P | Patient understanding of the aim and duration of treatment during the consent process | Gireesh Kumaran | ![]() |
![]() |
|||
159-P | Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma. | Rebecca Muirhead | ![]() |
![]() |
|||
160-P | Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours | giulia arrivi | ![]() |
![]() |
|||
162-P | Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer | Rebecca Muirhead | ![]() |
![]() |
|||
163-P | Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis | Ismael Ghanem | ![]() |
![]() |
|||
166-P | Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX | Muhammad Bilal Razzaq | ![]() |
![]() |
|||
168-P | Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter | WEN YU | ![]() |
![]() |
|||
169-P | Apatinib as non-first-line treatment in patients with advanced cholangiocarcinoma. | Jianzhen Lin | ![]() |
![]() |
|||
170-P | Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer | Ramos Maritza | ![]() |
![]() |
|||
174-P | Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer | Bin Sato | ![]() |
![]() |
|||
175-P | The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis. | BONG-HYEON KYE | ![]() |
![]() |
|||
176-P | Multicenter phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502) | Tetsuhito Muranaka | ![]() |
![]() |
|||
178-P | A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients | Vincenzo Formica | ![]() |
![]() |
|||
179-P | Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery | Rio Honma | ![]() |
![]() |
|||
180-P | A phase II study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403) | Naotoshi Sugimoto | ![]() |
![]() |
|||
181-P | Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma | Junichi Arita | ![]() |
![]() |
|||
182-P | Clinical importance of colonoscopy in patients with gastric cancer | Hee chan Yang | ![]() |
![]() |
|||
183-P | Legumain is a predictive effector of peritoneal metastasis for diffuse gastric cancer patients | Yan Wang | ![]() |
![]() |
|||
184-P | Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland | Miroslaw Jarosz | ![]() |
![]() |
|||
185-P | Is intra-arterial hepatic chemotherapy painful? | Fouad Kerbage | ![]() |
![]() |
|||
186-P | Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers | Andrea Mafficini | ![]() |
![]() |
|||
188-P | Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study | Kiyotaka Kawaguchi | ![]() |
![]() |
|||
191-P | Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND) | Jorge Aparicio | ![]() |
![]() |
|||
192-P | Complete peritonectomy versus ive peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes | ASHWIN KR | ![]() |
![]() |
|||
193-P | FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience | FRANCESCA FOSCHINI | ![]() |
![]() |
|||
194-P | Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences | SÍlvia Duarte | ![]() |
![]() |
|||
195-P | Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland | Miroslaw Jarosz | ![]() |
![]() |
|||
198-P | Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | ASHWIN KR | ![]() |
![]() |
|||
199-P | Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients | ASHWIN KR | ![]() |
![]() |
|||
200-P | Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer | ASHWIN KR | ![]() |
![]() |
|||
201-P | Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery | Michael Davidson | ![]() |
![]() |
|||
203-P | The role of combined treatment of metastatic colorectal cancer in patients with liver metastases | Danila Gridnev | ![]() |
![]() |
|||
204-P | Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer | Junghoon Bae | ![]() |
![]() |
|||
205-P | Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators | Adriana Novais Lopes Monteiro Soares | ![]() |
![]() |
|||
206-P | Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab | Zoubida Behourah | ![]() |
![]() |
|||
207-P | Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing | Lucia Ceniceros | ![]() |
![]() |
|||
208-P | Phase II study in progress to verify improved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer | Ahn Ann | ![]() |
![]() |
|||
209-P | Sorafenib in patients with hepatocellular carcinoma: 10 years of real life | Giulia Rovesti | ![]() |
![]() |
|||
210-P | Cytosponge for post-chemoradiation surveillance of oesophageal cancer: a feasibility study | SOMNATH MUKHERJEE | ![]() |
![]() |
|||
211-P | A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel | Cristina Morelli | ![]() |
![]() |
|||
213-P | CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX | José Francisco Rodríguez Hernández | ![]() |
![]() |
|||
214-P | Does PICC side matter? The experience at our hospital | Ana Gil Torralvo | ![]() |
![]() |
|||
215-P | Recurrence rate in colorectal adenocarcinoma patients receiving adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role? | Joseph Sgouros | ![]() |
![]() |
|||
216-P | Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma is Oral Capecitabine Non-Inferior to Paclitaxel Carboplatin Combination? | ALOKE GHOSH DASTIDAR | ![]() |
![]() |
|||
218-P | L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease | Athanasios Tampakis | ![]() |
![]() |
|||
219-P | Is there any affordable and reliable score in local gastric cancer? | Antia Cousillas | ![]() |
![]() |
|||
220-P | Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer | Tamar Esakia | ![]() |
![]() |
|||
221-P | Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid | Juan Jose Serrano Domingo | ![]() |
![]() |
|||
222-P | Patient-reported outcomes including LARS score and quality of life one year after chemoradiotherapy for anal cancer | Karen-Lise Garm Spindler | ![]() |
![]() |
|||
223-P | Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO) | Bettina Mller | ![]() |
![]() |
|||
224-P | HEPANOVA phase 2 study design: Tumor Treating Fields concomitant with sorafenib for the treatment of advanced hepatocellular carcinoma | James Wallis | ![]() |
![]() |
|||
226-P | Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer - Single-centre retrospective cohort analysis of 186 patients | Juraj Prejac | ![]() |
![]() |
|||
227-P | Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution. | Alberto Sánchez-Camacho Mejias | ![]() |
![]() |
|||
228-P | Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro | James Wallis | ![]() |
![]() |
|||
229-P | The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma | Catarina Quintela | ![]() |
![]() |
|||
230-P | EFFECTIVENESS OF CA 19.9 IN PREDICTING PROGNOSIS IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE | Stefano Mariani | ![]() |
![]() |
|||
231-P | Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients | Pop Vlad Vasile | ![]() |
![]() |
|||
232-P | RENCA MACROBEAD THERAPY (RMB): A BIOLOGICAL-SYSTEMS APPROACH TO METASTATIC COLORECTAL CANCER U.S. FDA BB-IND 10091 | Angelica Nazarian | ![]() |
![]() |
|||
233-P | Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience | Ravi Paluri | ![]() |
![]() |
|||
235-P | Induction Chemotherapy with Taxane versus Anthracycline-based Triplet for Locally Unresectable Nonmetastatic Gastric Cancer | Clara Borges | ![]() |
![]() |
|||
236-P | Histological Patterns and Clinical Characteristics of Metastatic Gastric Adenocarcinoma, Single institutional Experience in The Eastern Province of Saudi Arabia | Nedal Bukhari | ![]() |
![]() |
|||
237-P | Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment? | Tomislav Omrcen | ![]() |
![]() |
|||
238-P | Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy | Donna Stefanoni | ![]() |
![]() |
|||
239-P | Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis | Rafael Carmo | ![]() |
![]() |
|||
240-P | Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at ONeal Comprehensive Cancer Center | Ravi Paluri | ![]() |
![]() |
|||
243-P | A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis | Aysegl Ilhan-Mutlu | ![]() |
![]() |
|||
245-P | Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer | Ravi Paluri | ![]() |
![]() |
|||
246-P | The importance of laterality in colorectal cancer predicting response to therapeutics retrospective study evaluating differences between right and left colon in stage IV colon cancer | Élia Cipriano | ![]() |
![]() |
|||
247-P | SPLANCHNIC VEIN THROMBOSIS IN CHOLANGIOCARCINOMA. A RETROSPECTIVE OBSERVATIONAL STUDY. DONOSTIA UNIVERSITY HOSPITAL. | ANA LANDA MAGDALENA | ![]() |
![]() |
|||
248-P | Futility and Utility of Two-stage Hepatectomy | Miguel Cunha | ![]() |
![]() |
|||
250-P | The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows in vitro and in vivo efficacy in hepatocellular carcinoma | James Wallis | ![]() |
![]() |
|||
251-P | FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma | Joana Graa | ![]() |
![]() |
|||
253-P | Age vs Performance Status - Which is worst for surgery outcome? | Edgar Amorim | ![]() |
![]() |
|||
254-P | LIQUID BIOPSY FOR RAS MUTATIONAL STATUS ANALYSIS IN METASTATIC COLORECTAL CANCER | JOANA MARINHO | ![]() |
![]() |
|||
255-P | Outcomes of treatment for non-metastatic rectal cancer; a ten year single institute experience at the Bank of Cyprus Oncology Centre (BOCOC) | Ifigenia Konstantinou | ![]() |
![]() |
|||
256-P | Locally advanced unresectable and metastatic pancreatic cancer predictors of survival | Élia Cipriano | ![]() |
![]() |
|||
258-P | Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen | James Wallis | ![]() |
![]() |
|||
259-P | A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP signaling suppression of COX-2 in liver cancer | Yiguang Lin | ![]() |
![]() |
|||
260-P | PANOVA phase 3 study design: Tumor Treating Fields (150 kHz) in combination with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC) | James Wallis | ![]() |
![]() |
|||
262-P | Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome | MANOJ KUMAR | ![]() |
![]() |
|||
264-P | Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF- and IGF 1 signaling pathways | Yan Chen | ![]() |
![]() |
|||
265-P | RETROPERITONEAL LYMPH NODE METASTASES AS A PROGNOSIS FACTOR IN OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER | German Calderillo | ![]() |
![]() |
|||
266-P | Metastatic pancreatic cancer: Characteristics of long-term survivors | margaret mandelson | ![]() |
![]() |
|||
267-P | Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer | Tatiana Titova | ![]() |
![]() |
|||
268-P | Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer | Anup Kasi | ![]() |
![]() |
|||
269-P | PIPAC PACLITAXEL: A SYSTEMATIC AND PERITONEAL TISSUE PHARMACOKINETIC STUDY IN SWINE | Hon Lyn Tan | ![]() |
![]() |
|||
271-P | Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience | Anup Kasi | ![]() |
![]() |
|||
272-P | Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it. | Edgar Amorim | ![]() |
![]() |
|||
274-P | A MULTICENTER SPANISH RETROSPECTIVE STUDY OF PLATINUM-BASED CHEMOTHERAPY SENSITIVITY IN THE FIRST LINE SETTING AFTER RELAPSE FROM PERIOPERATIVE PLATINUM BASED CHEMOTHERAPY IN GASTRIC CANCER | Luis Paul Del Carpio Huerta | ![]() |
![]() |
|||
275-P | Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) | Massimiliano Salati | ![]() |
![]() |
|||
277-P | Socioeconomic and Administrative Factors Associated with Health&8209;care Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country | SYED ADIL HASSAN | ![]() |
![]() |
|||
279-P | Characterization of mismatch repair deficiency in biliary tract cancer | Caterina Vivaldi | ![]() |
![]() |
|||
281-P | EFFICACY OF A THERAPEUTIC EXERCISE PROGRAM ON AUTONOMIC NERVOUS SYSTEM FUNCTION, CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN COLORECTAL CANCER SURVIVORS: A RANDOMIZED CONTROLLED PILOT STUDY | Julia Ruiz-Vozmediano | ![]() |
![]() |
|||
283-P | Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis? | Malek Kreidieh | ![]() |
![]() |
|||
285-P | The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer | Rob Owens | ![]() |
![]() |
|||
286-P | The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with FIRST-LINE NAB-PACLITAXEL AND GEMCITABINE: POST-HOC ANALYSIS OF an Austrian multicenter, non-interventional study | Jakob M. Riedl | ![]() |
![]() |
|||
288-P | The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) | Debora Basile | ![]() |
![]() |
|||
289-P | Incidence and severity of cancer-related fatigue in gastric cancer patients | Bogdan Gafton | ![]() |
![]() |
|||
290-P | Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes | Kunal Kadakia | ![]() |
![]() |
|||
291-P | NRG1-fusion positive gastrointestinal tumours: Afatinib as a novel potential treatment option | Benjamin Weinberg | ![]() |
![]() |
|||
293-P | EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE) | Renato Cannizzaro | ![]() |
![]() |
|||
294-P | Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis | Lisa Salvatore | ![]() |
![]() |
|||
296-P | Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience | Andrea Pretta | ![]() |
![]() |
|||
297-P | Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease | Maria Radanova | ![]() |
![]() |
|||
298-P | Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro | Fenfang Wu | ![]() |
![]() |
|||
299-P | Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients | Silvia Catanese | ![]() |
![]() |
|||
300-P | Pancreatic Cancer resection in elderly patients: Analysis of outcomes | MARIANA GARCÍA VIROSTA | ![]() |
![]() |
|||
302-P | Prospective Evaluation of FOLFIRINOX in Neo-adjuvant Treatment of Gastro-Oesophageal Junction Carcinomas | Nicholas Travers | ![]() |
![]() |
|||
303-P | Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel | Adarsh Das | ![]() |
![]() |
|||
304-P | Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less | Adarsh Das | ![]() |
![]() |
|||
305-P | K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer | EDUARDO JOSÉ PERDOMO ZALDIVAR | ![]() |
![]() |
|||
306-P | Anal cancer outcomes and human immunodeficiency virus: a single-center experience | Carmen García Durán | ![]() |
![]() |
|||
307-P | Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results | Sarra Karrit | ![]() |
![]() |
|||
308-P | Role of TILS in predicting evolution of metastatic colorectal cancer | sonia ben nasr | ![]() |
![]() |
|||
310-P | Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma | Carles Fabregat Franco | ![]() |
![]() |
|||
314-P | Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)? | ROXANA REYES | ![]() |
![]() |
|||
315-P | ?Np73 and ?133p53 in liquid biopsy as early diagnostic markers for colorectal cancer | Javier Rodríguez-Cobos | ![]() |
![]() |
|||
316-P | Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India. | Prabhat Bhargava | ![]() |
![]() |
|||
317-P | Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study) | Maria Bensi | ![]() |
![]() |
|||
319-P | Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer | Lorenzo Fornaro | ![]() |
![]() |
|||
320-P | Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: real-world data of 13 oncological centers in Portugal | Tiago Cruz Tomás | ![]() |
![]() |
|||
321-P | Young Onset Rectal Cancer: a Therapeutic Challenge | Debapriya Mondal | ![]() |
![]() |
|||
323-P | Is FNA always necessary in submucosal lesion miming GIST? | Renato Cannizzaro | ![]() |
![]() |
|||
324-P | Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Experience | Rojymon Jacob | ![]() |
![]() |
|||
326-P | CLINICAL PRACTICE USE OF LIQUID BIOPSY TO IDENTIFY RAS/BRAF MUTATIONAL STATUS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): A SINGLE INSTITUTION EXPERIENCE | Vincenzo De Falco | ![]() |
![]() |
|||
327-P | Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction | OPEN HEALTH MEDICAL COMMUNICATIONS | ![]() |
![]() |
|||
328-P | Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey | Zorana Maravic | ![]() |
![]() |
|||
330-P | Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data | Pasquale Vitale | ![]() |
![]() |
|||
331-P | Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study. | Tomomi Kashiwada | ![]() |
![]() |
|||
332-P | A new prognostic score for biliary tract cancer: a multicenter experience | Pina Ziranu | ![]() |
![]() |
|||
333-P | Early fluorescence detection of oropharengeal and esophageal cancer | Rasul Sadykov | ![]() |
![]() |
|||
335-P | FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group). | Federico Longo Muñoz | ![]() |
![]() |
|||
339-P | Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia | Imtinen Belaid | ![]() |
![]() |
|||
341-P | Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study | Angela Zambrano | ![]() |
![]() |
|||
344-P | Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center | Angela Zambrano | ![]() |
![]() |
|||
346-P | A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors | Ines Rego | ![]() |
![]() |
|||
347-P | THE RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) UNDER IMATINIB MESYLATE TREATMENT | DIMITRIOS TZILVES | ![]() |
![]() |
|||
348-P | Esophageal cancer: about 42 cases Experience of the medical oncology department of Hassan II University Hospital of Fez, Morocco | Nouiakh Lamyae | ![]() |
![]() |
|||
350-P | Management of gallbladder cancer - EXPERIENCE OF MEDICAL ONCOLOGY DEPARTMENT ABOUT 140 CASES | Nouiakh Lamyae | ![]() |
![]() |
|||
352-P | Prognostic Value, Clinicopathologic Features and Diagnostic Accuracy of Interleukin-8 in Colorectal Cancer: A prospective study in 60 patients in Tunisia. | Sarra Karrit | ![]() |
![]() |
|||
353-P | Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX | Hanane Fatima Zahra Aliane | ![]() |
![]() |
|||
354-P | Survival and prognostic factors of localized gastric carcinomas (about 50 cases). Experience of the medical oncology department of Hassan II University of Fez | hayat erraichi | ![]() |
![]() |
|||
355-P | To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology | Pujarini Dash | ![]() |
![]() |
|||
356-P | COLORECTAL CANCER IN YOUNG TUNISIAN PATIENTS: clinical, histopathological and RAS testing data | HAYFA GUETTITI TOUNSI | ![]() |
![]() |
|||
357-P | The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer | Hanane Fatima Zahra Aliane | ![]() |
![]() |
|||
362-P | Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study | Solene Doat | ![]() |
![]() |
|||
364-P | High expression of oestrogen receptor beta correlates with anti-tumorigenic inflammatory proteins in colorectal cancer. | Geriolda Topi | ![]() |
![]() |
|||
366-P | Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer | Enas Elkhouly | ![]() |
![]() |
|||
367-P | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer | Joana Simes | ![]() |
![]() |
|||
368-P | Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemotherapy and surgery in locally advanced rectal cancer: a retrospective analysis of a single center experience | Bárbara Lima | ![]() |
![]() |
|||
369-P | Home chemotherapy in colorectal cancer: First experience in Argentina | guillermo streich | ![]() |
![]() |
|||
370-P | Role of radiotherapy in local control of metastatic rectal cancer: a single-center experience | Ana Afonso | ![]() |
![]() |
|||
371-P | Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally advanced rectal cancer: A phase 2 trial | Seihwan You | ![]() |
![]() |
|||
375-P | Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers | SOUMIA berrad | ![]() |
![]() |
|||
376-P | Primary malignant tumors of the small intestine: clinical and therapeutic aspects | SOUMIA berrad | ![]() |
![]() |
|||
381-P | The management of neuroendocrine gastroenteropancreatic tumors. | SOUMIA berrad | ![]() |
![]() |
|||
382-P | Clinicopathologic feature of microsatellite stable early-onset colorectal cancer | Rumi Shin | ![]() |
![]() |
|||
383-P | Survival and prognostic factors for stage II colon cancer | SOUMIA berrad | ![]() |
![]() |
|||
384-P | Anal Carcinoma A comparative analysis of the standard treatment vs An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México. | Jesús Zamora | ![]() |
![]() |
|||
385-P | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib | Long Pan | ![]() |
![]() |
|||
389-P | Clinical Significance of BRAF Mutations in Colorectal Cancer: A Retrospective Study of One Institution in a real-life population. | Lidia Carnerero Córdoba | ![]() |
![]() |
|||
392-P | Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment | Yestay Abzalbek | ![]() |
![]() |
|||
395-P | Expression of MMR in Women High Grade Carcinoma of Unknown Primary | Joni Howells | ![]() |
![]() |
|||
398-P | The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital | Michael Davidson | ![]() |
![]() |
|||
399-P | How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases | Syrine SGHAIER | ![]() |
![]() |
|||
402-P | Incidence and mortality rates of cholangiocarcinoma in England | Tracey Genus | ![]() |
![]() |
3-6 July 2019 Barcelona
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|